MAHDL01

**MAHDL01** is an investigational, plant-based pharmaceutical mixture developed by Mazal Plant Pharmaceuticals, with Advanced Plant Pharmaceuticals as its parent developer. It was reported to consist of a combination of whole plants and to be intended to improve the HDL/LDL cholesterol ratio for treatment of hypercholesterolemia or hyperlipidemia. In 2005, Mazal reported FDA clearance of an Investigational New Drug application and planned Phase I/II development; the specific botanical constituents, molecular target, formulation, route, and clinical-development outcomes have not been publicly disclosed. ([allstocks.com](https://www.allstocks.com/stockmessageboard/cgi-bin/ultimatebb.cgi?ubb=print_topic%3Bf%3D2%3Bt%3D007975))